Related Experiment Video
Updated: Aug 9, 2026
12:26
Identification of Cyclin-dependent Kinase 1 Specific Phosphorylation Sites by an In Vitro Kinase Assay
Published on: May 3, 2018
Expression, purification, and circular dichroism analysis of human CDK9
Andreia Machado Leopoldino1, Fernanda Canduri, Hamilton Cabral
1Faculdade de Medicina de São José do Rio Preto, SP, Brazil.
Protein Expression and Purification
|April 4, 2006
Summary
Researchers successfully expressed and purified human cyclin-dependent kinase 9 (CDK9) in E. coli. Structural analysis confirmed its secondary structure, paving the way for developing CDK9 inhibitors.
Area of Science:
- Biochemistry
- Molecular Biology
- Structural Biology
Background:
- Cyclin-dependent kinase 9 (CDK9) is a crucial regulator of transcription.
- Dysregulation of CDK9 is implicated in various diseases, highlighting its therapeutic potential.
- Developing specific CDK9 inhibitors requires a well-characterized recombinant protein.
Purpose of the Study:
- To establish a method for the recombinant expression and purification of human CDK9.
- To perform initial structural characterization of the purified human CDK9.
- To lay the groundwork for future drug discovery efforts targeting CDK9.
Main Methods:
- Human CDK9 gene cloned into the pET23a expression vector.
- Protein expression in E. coli BL21 at 30°C.
- Purification utilizing ion exchange and ATP-affinity chromatography.
- Circular dichroism spectroscopy for structural analysis.
Main Results:
- Several milligrams of soluble recombinant human CDK9 were successfully purified.
- Circular dichroism analysis indicated approximately 26% helical content in the protein structure.
- Structural models were consistent with the experimental spectroscopic data.
Conclusions:
- This study reports the first successful expression and structural analysis of human CDK9 in E. coli.
- The established purification protocol yields sufficient protein for further structural and biochemical studies.
- This work represents a critical first step towards the rational design and development of novel CDK9 inhibitors.
